Answers are grounded in this paper and cite their sources.
Daily recombinant growth hormone (GH) restores normal growth and body composition in GH-deficient children and adults; however, daily injections are inconvenient and can be distressing for some children. On top of this compliance is a problem in up to 75% of children. Developing long-acting GH formulations has proved challenging, and questions remain regarding safety and efficacy. In this review, we focus on the rationale for generating long-acting GH agonists and the technologies being developed to deliver prolonged exposure to GH.
No takes yet. Share an insight, caveat, or question.
Cawley et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: